Japan 2012 NHI Price Revision Takes Shape, Long-Listed Products See Smaller Cuts Than Expected
This article was originally published in PharmAsia News
Japan's MHLW and Finance Ministry face off on the steps needed to shave reimbursement costs.
You may also be interested in...
The new chairman of Japan's Central Social Medical Insurance Council (Chuikyo), the committee that determines drug pricing for Japan's National Health Insurance, will consider the possibility of linking drug pricing to health technology assessments, similar to the UK's National Institute for Health and Clinical Excellence
An experimental drug pricing policy to shelter selected new drugs from price cuts will be high on the agenda for Japan's reimbursement body, the Central Social Medical Insurance Agency, for the coming year, according to the agency's just-released schedule for hearings and discussions for 2011